U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Dec 16 11:19:22 GMT 2023
Edited
by admin
on Sat Dec 16 11:19:22 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED
Sequence Type COMPLETE
Record UNII
2BN89552WP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IFABOTUZUMAB
INN   USAN  
INN   USAN  
Official Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN EPHA RECEPTOR EPHA3) (HUMAN MONOCLONAL KB004 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL KB004 .KAPPA.-CHAIN, DIMER
Common Name English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS EPHA3(EPHRIN RECEPTOR A3, EPH RECEPTOR A3, EPHRIN TYPE-A RECEPTOR 3, TYROSINE PROTEIN KINASE TYR04, TYROSINE-PROTEIN KINASE RECEPTOR REK4, ETK, ETK1, HEK, HEK4)), HUMANIZED MONOCLONAL ANTIBODY
Common Name English
FIBATUZUMAB
WHO-DD  
INN  
Official Name English
ifabotuzumab [INN]
Common Name English
Ifabotuzumab [WHO-DD]
Common Name English
Code System Code Type Description
CAS
1234137-51-9
Created by admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
PRIMARY
INN
10149
Created by admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
PRIMARY
FDA UNII
2BN89552WP
Created by admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
PRIMARY
USAN
DE-43
Created by admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
PRIMARY
NCI_THESAURUS
C116629
Created by admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
PRIMARY
From To
1_22 1_96
1_145 1_201
1_262 1_322
1_368 1_426
2_22 2_96
2_145 2_201
2_262 2_322
2_368 2_426
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
1_221 3_214
2_221 4_214
1_227 2_227
1_230 2_230
Glycosylation Type MAMMALIAN, AFUCOSYLATED
Glycosylation Link Type Site
N 1_298
N 2_298
Related Record Type Details
TARGET->LIGAND
EphA3 is an oncofetal antigen with restricted tissue expression, the development of a targeted agent holds promise. Four mechanisms of cell killing have been described: direct induction of apoptosis, activation of antibody-dependent cell-mediated cytotoxicity (ADCC), disruption of tumor vasculature and inhibition of survival signaling from the marrow microenvironment.
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL